• Home
  • Journalists
    • Headlines
  • Community
    • Businesses
    • Jobs
    • Learning
    • Marketplace
  • Store
(@)

Ozempic Maker’s Stock Plunges 20% After Profit Warning

Novo Nordisk slashed its financial forecasts as it struggled to fight off competition in the United States. It also named a new chief executive, who highlighted the “urgency” of the moment.

Eshe Nelson
Author: Eshe Nelson

Written by

Eshe Nelson

in

Appointments and Executive Changes, Drugs (Pharmaceuticals), GLP-1 RAs (Drug), Novo Nordisk A/S, Ozempic (Drug), Stocks and Bonds
←In The Chair With: Taraji P. Henson’s Makeup Artist Keita Moore
Morton Mintz, Muckraking Crusader for Consumers, Dies at 103→

More posts

  • Trump cancels U.S. officials’ trip to Pakistan for Iran negotiations

  • The best, weirdest and most emo moments of Stagecoach Day 1

  • Budget Rent a Car heiress assaulted and strangled during a California home invasion

  • Nebraska should support the Democrat whose win won’t erase its ‘blue dot’

About Us


Support Us

Trademark & Copyright 1998 – 2025 · MOSAEC

  • Facebook
  • Instagram
  • LinkedIn
  • YouTube